Biogen discloses PML cases, one death in Tysabri patients

Four more patients taking Biogen Idec's multiple sclerosis drug Tysabri have developed the serious brain infection known as progressive multifocal leukoencephalopathy (PML), and one of them died, according to the company's monthly update. That brought the total number of confirmed cases as of Dec. 2 to 79, with 16 deaths. Report

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

The FDA approved Lundbeck's Vyepti, formerly known as eptinezumab, as the first IV therapy to prevent migraines in adults.